Companies › Benitec Biopharma
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Nov 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BB-301 AAV9-delivered gene therapy encoding codon-optimized wildtype PABPN1 protein and 2 shRNAs | PABPN1 | Phase 1 | Oculopharyngeal Muscular Dystrophy | Nov 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06185673 | BB-301 | Phase 1 | Oculopharyngeal Muscular Dystrophy | Neurology | Nov 2030 |
Cash of $180m on 2026-06-30; operating cash outflow about $17m a year; runway about 130 months at that burn, to May 2037
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.